

Identification of research trends concerning application of stent implantation in the treatment of pancreatic diseases by quantitative and biclustering analysis: a bibliometric analysis

Xuan Zhu^{1,2}, Xing Niu³, Tao Li⁴, Chang Liu⁵, Lijie Chen⁶, Guang Tan^{Corresp. 7}

¹ Department of Pancreatic and Biliary Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

² Department of General Surgery, Anshan Hospital, First Affiliated Hospital of China Medical University, Anshan, Liaoning, China

³ Department of Second Clinical College, Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

⁴ Department of General Surgery, Fushun Mining Bureau General Hospital, Fushun, Liaoning, China

⁵ Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

⁶ Department of Third Clinical College, China Medical University, Shenyang, Liaoning, China

⁷ Department of Hepatobiliary Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

Corresponding Author: Guang Tan

Email address: guangtan@dmu.edu.cn

Objectives: In recent years, with the development of biological materials, the types and clinical applications of stents have been increasing in pancreatic diseases. However, relevant problems are also constantly emerging. Our purpose was to summarize current hotspots and explore potential topics in the fields of the application of stent implantation in the treatment of pancreatic diseases for future scientific research.

Methods: Publications on the application of stents in pancreatic diseases were retrieved from PubMed without language limits. High-frequency Medical Subject Headings (MeSH) terms were identified through Bibliographic Item Co-Occurrence Matrix Builder (BICOMB). Biclustering analysis results were visualized utilizing the gCLUTO software. Finally, we plotted a strategic diagram.

Results: 4087 relevant publications were obtained from PubMed until May 15th, 2018. 83 high-frequency MeSH terms were identified. Biclustering analysis revealed that these high-frequency MeSH terms were classified into 8 clusters. After calculating the density and concentricity of each cluster, strategy diagram was presented. The cluster 5 “complications such as pancreatitis associated with stent implantation” was located at the fourth quadrant with high concentricity and low density.

Conclusions: In our study, we found 8 topics concerning the application of stent implantation in the treatment of pancreatic diseases. How to reduce the incidence of postoperative complications and improve the prognosis of patients with pancreatic diseases by stent implantation could become potential hotspots in the future research.

1 **Identification of research trends concerning application of stent implantation**
2 **in the treatment of pancreatic diseases by quantitative and biclustering**
3 **analysis: a bibliometric analysis**

4 **Running title: Stent implantation in pancreatic diseases**

5
6 **Xuan Zhu, Xing Niu, Tao Li, Chang Liu, Lijie Chen, Guang Tan***

7
8 **Xuan Zhu**, Department of Pancreatic and Biliary Surgery, First Affiliated Hospital of China
9 Medical University, & Department of General Surgery, Anshan Hospital, First Affiliated
10 Hospital of China Medical University, No.155 Nanjing North Street, Heping District, Shenyang
11 110001, Liaoning Province, China. 2382942812@qq.com

12 **Xing Niu**, Department of Second Clinical College, Shengjing Hospital affiliated to China
13 Medical University, NO.36 Sanhao Street, Heping District, Shenyang 110004, Liaoning
14 Province, China. 605398920@qq.com

15 **Tao Li**, Department of General Surgery, Fushun Mining Bureau General Hospital, No.24 Central
16 Street, Xinfu District, Fushun 113008, Liaoning Province, China. 1309359604@qq.com

17 **Chang Liu**, Department of General Surgery, First Affiliated Hospital of China Medical
18 University, No.155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province,
19 China. 466040666@qq.com

20 **Lijie Chen**, Department of Third Clinical College, China Medical University, NO.77 Puhe
21 Road, Shenyang North New Area, Shenyang 110122, Liaoning Province, China.
22 2084534914@qq.com

23
24 **Supportive foundations:** Not applicable.

25
26 **Author contributions:** Tan G conceived and designed the study. Zhu X, Niu X conducted most
27 of the experiments and data analysis, and wrote the manuscript. Li T, Liu C and Chen LJ
28 participated in collecting data and helped to draft the manuscript. All authors reviewed and
29 approved the manuscript.

30
31 **Conflict-of-interest statement:** The authors declare no conflicts of interest.

32
33 **Correspondence to: Guang Tan, Professor**, Department of Hepatobiliary Surgery, First
34 Affiliated Hospital of Dalian Medical University, No.222 Zhongshan Road, Dalian 116027,
35 Liaoning Province, China. guangtan@dmu.edu.cn

37 **Abstract:**

38 **Objectives:** In recent years, with the development of biological materials, the types and clinical
39 applications of stents have been increasing in pancreatic diseases. However, relevant problems
40 are also constantly emerging. Our purpose was to summarize current hotspots and explore
41 potential topics in the fields of the application of stent implantation in the treatment of pancreatic
42 diseases for future scientific research.

43 **Methods:** Publications on the application of stents in pancreatic diseases were retrieved from
44 PubMed without language limits. High-frequency Medical Subject Headings (MeSH) terms were
45 identified through Bibliographic Item Co-Occurrence Matrix Builder (BICOMB). Biclustering
46 analysis results were visualized utilizing the gCLUTO software. Finally, we plotted a strategic
47 diagram.

48 **Results:** 4087 relevant publications were obtained from PubMed until May 15th, 2018. 83 high-
49 frequency MeSH terms were identified. Biclustering analysis revealed that these high-frequency
50 MeSH terms were classified into 8 clusters. After calculating the density and concentricity of
51 each cluster, strategy diagram was presented. The cluster 5 “complications such as pancreatitis
52 associated with stent implantation” was located at the fourth quadrant with high centricity and
53 low density.

54 **Conclusions:** In our study, we found 8 topics concerning the application of stent implantation in
55 the treatment of pancreatic diseases. How to reduce the incidence of postoperative complications
56 and improve the prognosis of patients with pancreatic diseases by stent implantation could
57 become potential hotspots in the future research.

58 **Key words:** Hotspots; Stents; Pancreatic diseases; Bibliometrics; MeSH terms

59 **Introduction:**

60 In recent years, stents play an increasingly essential part in pancreatic diseases such as
61 plastic stents, self-expanding metal stents, biodegradable stents, radioactive particle stents and so
62 on. As an example, the covered metal stents reduce the incidence of complications of biliary
63 obstruction caused by pancreatic cancer. It has been reported that percutaneous insertion of short
64 metal stents supplies for a secure treatment, which is beneficial for patients in resectable
65 pancreatic head cancer with jaundice [1]. With in-depth research, an irradiation pancreatic stent
66 may provide longer patency and better patient survival [2]. And endoscopic application
67 significantly improves the therapeutic effect of pancreatic stent [3]. Pancreatic cancer is a
68 common digestive system cancer with high mortality. And the 5-year survival rate has increased
69 from 3% to 8% over the past decade years [4-5]. So far, surgical resection is the only possible
70 treatment option. However, postoperative complications worsen the patient's prognosis and have
71 been one of the leading causes of death after surgery. Multiple plastic stents or covered self-
72 expandable metallic stent could relief bile duct stricture caused by chronic pancreatitis [6].

73 There have been few studies on the application of stents in pancreatic diseases by use of
74 bibliometrics. Bibliometric method, as a quantitative analysis method, is used to determine the
75 evolution of science exploration over the past decade years [7-8]. Co-word analysis is an

76 important scientometric method for identifying research hotspots in a certain field. Co-word
77 analysis was proposed by French bibliographers in the 1970s. Its principle is mainly to count the
78 frequency of simultaneous occurrence of words in the literature. The clustering analysis,
79 association analysis, multi-dimensional scale analysis and other methods are utilized to analyze
80 the relationship between words [9]. Therefore, co-word analysis can be used to outline the
81 current state of literature research in a field and to predict the future trends [10]. Co-word
82 analysis method reveals the intricate relationships between many objects in an intuitive way such
83 as numerical values and graphics. Therefore, it can avoid the subjective problems brought by the
84 previous reviews which were summarized by authors. Cluster analysis can be used to obtain
85 semantic relationships for research topics [12]. In our study, we made double-clustering analysis,
86 which can cluster the rows and columns of a matrix simultaneously [13]. Therefore, it can easily
87 cluster global information and analyze high-dimensional data. The strategic diagram is used to
88 describe the internal contact situation and the interaction between the fields in a research field
89 based on the co-word matrix and clustering analysis, and further analyze the development of
90 research hotspots in a certain subject. The strategic diagram displays the positional relationship
91 of the clusters in the plane coordinates in a visual form. The quadrant structure and changes of
92 the research subject are described according to the position and variation of the quadrant of the
93 cluster.

94 Hence, we constructed a bibliometric analysis by co-word analysis and visualization
95 concerning the application of stents in pancreatic diseases. And strategic diagram was
96 established to explore the development status.

97 **Materials and methods:**

98 **Data obtaining**

99 All publications came from PubMed without the restrictions of languages. The PubMed
100 database has been used to retrieve data in some of the biomedical research [14, 15]. PubMed is
101 chosen not only because of the authority and breadth of the literature, but also the normative
102 nature of the Medical Subject Headings (MeSH) keywords, more importantly. MeSH has been
103 applied to index and catalog articles in PubMed. In our study, we collected literature on the
104 application of stents in pancreatic diseases on May 15th, 2018, in order to ensure more current
105 research results. Our research strategy was as follows: ("stents"[MeSH Terms] OR "stents"[All
106 Fields] OR "stent"[All Fields]) AND (("pancreas"[MeSH Terms] OR "pancreas"[All Fields] OR
107 "pancreatic"[All Fields]) OR ("pancreatitis"[MeSH Terms] OR "pancreatitis"[All Fields])) and
108 "2018/05/15" [PDAT]. Publication trends were retrieved from GoPubMed
109 (<http://www.gopubmed.org>) [16].

110 **Literature screening criteria**

111 If a paper concerning application of stents in pancreatic diseases was an original article, we
112 would accept the literature. Meanwhile, media coverage and science briefings were excluded.
113 Furthermore, two researchers separately examined the papers by title, abstract and full text. One
114 researcher excluded 20 articles, and the other researcher excluded 19 articles. And the agreement
115 was 95%, which suggested a strong correlation [17]. Finally, title, author, institution, country,

116 publication year and MeSH terms of available articles were saved into a new file in XML.

117 **Data extraction and analysis**

118 XML file was imported into BICOMB for data extraction [18-20]. And authors, journals
119 and the frequency ranking of MeSH terms were determined [21, 22]. According to H index, the
120 terms were first sorted in descending order of terms. Then the high-frequency major MeSH terms
121 were identified if a term with frequency greater than or equal to its sequence number (h) from the
122 list of high frequency terms, and h was the threshold for intercepting high frequency terms. Then
123 the relationships between the high-frequency major MeSH terms and the source literature were
124 determined utilizing biclustering analysis. And a binary matrix was produced using the source
125 literature set generated by BICOMB and the high-frequency MeSH terms as columns and rows.

126 **Cluster analysis**

127 Then, double clusters and visual analysis were performed by "gCLUTO" version 1.0
128 software. "gCLUTO" is a graphical cluster toolkit and graphical front-end of the "CLUTO" data
129 clustering library [23, 24]. The clustering analysis was employed to assess the high-frequency
130 MeSH terms. The clustering method was used to repeat the bisection, cosine as the similarity
131 function, and I2 as the clustering criterion function. By use of different numbers of clusters, 2
132 clusters were performed to differentiate the first-rank number of clusters. And the visualizations
133 of high frequency and high-frequency bifocal results with MeSH article were constructed by use
134 of Alpine and Matrix. By means of the semantic corrections between the MeSH terms and the
135 content of typical articles in every group, the relevant topics on the application of stents in
136 pancreatic diseases were obtained. And we made a visualized matrix biclustering of high-
137 frequent major MeSH terms and PubMed Unique Identifiers (PMIDs) of articles on the
138 application of stents in pancreatic diseases.

139 **Strategic diagram analysis**

140 A two-dimensional table is depicted by plotting themes based on centrality and density.
141 The X-axis stands for centrality, namely the closeness between keywords within this category
142 and those within other categories. It indicates the degree of interaction between a subject area
143 and other subject areas. The Y-axis represents density, namely the closeness of the keywords
144 within each category. And it indicates that this category maintains and develops its own
145 capabilities [25]. The above eight categories were assigned to the four quadrants based on the
146 results of the cluster analysis. In addition, excel was utilized to generate strategic diagram.

147 **Social network analysis**

148 The high frequency MeSH terms co-occurrence matrix was imported into the Ucinet 6.0
149 (Analytic Technologies Co., Lexington, KY, USA) software. And the social network analysis
150 method was utilized to analyze the subject and knowledge structure of the application of stents in
151 pancreatic diseases. Then the high-frequency MeSH term network was visualized by NetDraw
152 2.084 software. The nodes represent MeSH terms, and the links stand for the co-occurrence
153 frequency of these terms. And we measured the degree, betweenness and closeness centralities of
154 every node. At the same time, author relationship network was constructed by above methods.

155 **Results:**

156 Overall evaluation

157 Based on GoPubMed, we obtained the literature information according to the search
158 strategy: stents [MeSH] and pancreas [MeSH] or “pancreatic diseases” [MeSH]. **Figure 1A**
159 depicts the distribution of the publication year of corresponding papers. The first article was
160 published in 1977. As time went by, the volume of publications increased year by year. By 2015,
161 it had a downward trend. **Figure 1B** shows the volume of paper outputs concerning the
162 application of stents in pancreatic diseases in first 20 countries. And the map was generated by
163 an online website (pixelmap.amcharts.com). The number in the map is the quantity of associated
164 publications for every country or region. The United States stands first with 1167 publications.
165 Furthermore, we summarized the annual distribution of MeSH terms associated with the
166 application of stents in pancreatic diseases (**Figure 1C**). Different colors represent different
167 highly frequent major MeSH terms. We found that these MeSH terms had roughly the same
168 development trend every year from 1985-2018, indicating that they had close associations. As
169 shown in **Table 1**, the top 29 authors with a cumulative percentage of 27.9483 are listed. “Baron
170 TH” (84, 2.0468%), “Kahaleh M” (81, 1.9737%) and “Isayama H” (65, 1.5838%) are the top
171 three authors. From 1977 to 2018, the 25 most active journals published publications on the
172 application of stents in pancreatic diseases account for 49.92% of all publications. **Table 2**
173 demonstrates the 25 most productive journals, as the core journals in the research fields on the
174 application of stents in pancreatic diseases under Bradford’s Law. “Gastrointestinal endoscopy”,
175 “Endoscopy”, “World journal of gastroenterology” are the most active three journals.

176 **Figure 1. The information of literature on the application of stents in pancreatic diseases.**

177 **A. The growth of literature publications about the application of stents in pancreatic**
178 **diseases from 1977 to 2018; B. Geographic distribution of research outputs on the**
179 **application of stents in pancreatic diseases; C. Annual distribution of MeSH terms about**
180 **the application of stents in pancreatic diseases**

181 **Table 1. The 29 top authors from the listed publications on the application of stents in**
182 **pancreatic diseases (PubMed sourced until May 2018)**

183 **Table 2. Most active journals on the topic of the application of stents in pancreatic diseases**
184 **(PubMed sourced until May 2018)**

185 **High-frequent major MeSH terms**

186 4087 articles were selected until May 15th, 2018. 83 high-frequency MeSH terms were
187 extracted from the listed publications, with a cumulative percentage of 57.5291 (**Table 3**).
188 “Stents” (2238, 3.8488%), “Treatment Outcome” (1038, 1.7851%) and “Retrospective Studies”
189 (758, 1.3036%) are the top three MeSH terms.

190 **Table 3. 83 high-frequent major MeSH terms from the listed publications on the**
191 **application of stents in pancreatic diseases**

192 **Cluster analysis**

193 The double cluster analysis results were visualized into mountain visualization and
194 hierarchical cluster tree. In the mountain visualization, the peak and matrix visualizations express
195 the high-frequency MeSH terms. Each cluster represents a peak marked by cluster number 0-7 in
196 **Figure 2**, and the related clusters are described according to the volume, color and height of the

197 peaks. The volume of the peak is directly proportional to the number of MeSH terms in the
198 cluster. In the meanwhile, the internal standard deviation of a cluster object is represented by the
199 color of the peak. Blue stands for the high deviation and red represents the low deviation. The
200 peak is the position relative to the other clusters. The closer the distance between the two peaks,
201 the higher the similarity between the two clusters. The height and similarity of each cluster are
202 proportional to each other.

203 In **Figure 3**, the row labels represent high-frequency MeSH terms, and the PMIDs locate
204 the column labels at the right and bottom of the matrix. The color of each grid suggests the
205 frequency of appearance in a paper. The darker the red, the greater the frequency. 83 high-
206 frequency major MeSH terms are distinguished into 8 clusters in matrix visualization. The top
207 and left of hierarchical tree respectively indicate the relationships among the major MeSH terms
208 and the associations among the papers. Meanwhile, the corresponding article is obviously shown
209 for each high frequency MeSH terms in each cluster.

210 **Figure 2. A mountain visualization biclustering of 83 high-frequent major MeSH terms and**
211 **papers on the application of stents in pancreatic diseases**

212 **Figure 3. A visualized matrix biclustering of highly frequent major MeSH terms and**
213 **PubMed Unique Identifiers (PMIDs) of articles on the application of stents in pancreatic**
214 **diseases**

215 **Strategic diagram**

216 The centrality and density of the 8 clusters are listed in **Table 4**. The details of MeSH terms
217 and clusters are shown in **Table 5**. In **Figure 4**, x-axis represents the centrality, and y-axis stands
218 for the density on the strategy diagram. The four quadrants clockwise from the upper right corner
219 express the first quadrant, the second quadrant, the third quadrant and the fourth quadrant. As
220 shown in **Figure 4A**, the clusters in the first quadrant are suggested to be central topics in the
221 network (due to their strong connection with other clusters) and have intense internal
222 relationships (due to high degree of development). The clusters in the second quadrant are
223 peripheral, however, already well-developed topic. The clusters in the third quadrant are both
224 peripheral and undeveloped. The clusters in the fourth quadrant are central and undeveloped, but
225 they are becoming mature to some extent [26].

226 **Figure 4B** depicts that cluster 1 and cluster 3 are located in the first quadrant, suggesting
227 that the cluster densities and centrality degrees are all high, that is to say, the MeSH terms in
228 cluster 1 and cluster 3 are closely linked, and research tends to be well-developed. And the
229 orientation is high, indicating that it is at the center of the research network. Cluster 4 and 7 are
230 located in the second quadrant with high density and low centrality, indicating that internal links
231 are close together with a clear topic. The research on this topic is shown to be relatively well-
232 developed, with little correlation with other research. Cluster 0, 2 and 6 are located in the third
233 quadrant, with low density and centrality. MeSH terms of Cluster 0, 2 and 6 are the margins of
234 the entire field. The internal structure is relatively loose and research is yet developed. Cluster 5
235 is located in the fourth quadrant with low density and high centrality, indicating that it has close
236 relations with other research. However, the research is not found to be well-developed. The
237 research on this topic has potential value, and is now in the exploratory stage; however, more

238 research is required.

239 **Table 4. The centrality and density of the 8 clusters about the application of stents in**
240 **pancreatic diseases**

241 **Table 5. The cluster analysis of 8 clusters the application of stents in pancreatic diseases.**

242 **Figure 4. Strategic diagram for the application of stents in pancreatic diseases. (A) The**
243 **meaning of strategic diagram. (B) The strategic diagram of the 8 clusters for the**
244 **application of stents in pancreatic diseases**

245 **Social network analysis**

246 As shown in **Figure 5A**, we constructed the author relationship network. There are 29 nodes
247 which represent 29 authors. The size and location of nodes suggests the decisive role of an
248 author. Links indicate the connection between two authors. In **Figure 5A**, the node “Itoi T” was
249 the largest one, which was located in the center of the social network, followed by “Isayama H”
250 and “Sasaki T”. Therefore, these authors could play a critical role in the field of the application
251 of stents in pancreatic diseases. Their articles could represent the maturity of the research area
252 and hot spots. **Figure 5B** depicts that the network relationships among 83 high-frequent major
253 MeSH terms. The size of nodes suggests the centrality of high-frequent major MeSH terms. In
254 the meanwhile, the thickness of the lines demonstrates the co-occurrence frequency of keywords
255 pairs.

256 **Figure 5. Social network analysis. A. The top 29 author relationship network. The size and**
257 **location of nodes represent the centrality of an author in the social network. B. The**
258 **network of high-frequent major MeSH terms. Nodes suggest high-frequent major MeSH**
259 **terms. The size and location of nodes represent the centrality of a MeSH term in the**
260 **network structure map. Links stand for the connection between MeSH terms, and the**
261 **number or thickness of the lines stands for the co-occurrence frequency of high-frequent**
262 **major MeSH terms**

263 **Discussion:**

264 We took advantage of GoPubMed to analyze the publication trends in the field of pancreatic
265 stents. Before 2015, the volume of relevant publications was continuously rising and relative
266 research interest was fluctuating rising. However, beginning with 2015, the volume of
267 publications and relative research interest both showed a downward trend, which suggests that
268 the researchers' interest have shifted and more innovation needs to be explored in the pancreatic
269 stents. In addition, we also focused on the countries and author of research outputs. The United
270 States, Japan and Germany remain to be the countries with the largest number of publications on
271 pancreatic stents. The results indicated the developed countries occupied main position in the
272 field. After measuring the top 29 authors on pancreatic stents, we made the author relationship
273 network. The authors in the field have close cooperation, emphasizing the importance of
274 cooperation. By paying attention to these authors, we would have a general understanding of the
275 research direction and hotspots in this field. In order to further track research trends, journals are
276 also the focus of attention. Therefore, we measured the most active journals, considering as the
277 central journals in the relevant fields such as Gastrointestinal endoscopy, Endoscopy, World

278 journal of gastroenterology. The high-frequency MeSH terms may reflect the research hot spots.
279 The 83 high-frequency major MeSH terms were achieved by the co-occurrence in the same
280 paper, which represented the research content in the field. Yearly distribution trends on different
281 MeSH terms had the same fluctuating trend.

282 83 hot major MeSH terms were clustered into 8 clusters. The network revealed that these
283 MeSH terms existed complex relationship network. Endoscopic retrograde ERCP in acute and
284 chronic pancreatitis and imaging methods as an auxiliary method of stent placement are located
285 in the second quadrant. Cluster 1 and 3 are located in the first quadrant, including the
286 complications of stent placement in bile duct neoplasms and pancreatic neoplasms and stents for
287 the prevention of pancreatic fistula following pancreaticoduodenectomy. The two topics are
288 current research center and hot topics for pancreatic stents. And cluster 0, 2, 6 are located in the
289 third quadrant, which suggesting that the three topics are at the margin and not yet mature,
290 including stents placement in pancreatic neoplasms, the postoperative complications after stent
291 placement therapy such as pancreaticoduodenectomy and pancreatic ducts changes for patients in
292 chronic pancreatitis. In the meanwhile, complications such as pancreatitis associated with stent
293 implantation could have potential research value in the fourth quadrant, which are the research
294 center, however, not yet mature. Therefore, the topic could become potential hotspots in the
295 future science research. Then the 8 topics would be introduced respectively.

296 **Stents placement in pancreatic neoplasms**

297 Increasing numbers of patients with resectable pancreatic neoplasms are receiving
298 neoadjuvant therapy such as stents placement. Tumor growth in pancreatic neoplasms often leads
299 to invasion of other organs and biliary obstruction, resulting in repeated stent placement [27].
300 The self-expandable metal stents possess effectiveness and safety in achieving durable biliary
301 drainage for patients with pancreatic neoplasms [28, 29]. For example, the covered self-
302 expanding metal stents is used for the therapy of biliary tract hemorrhage induced by advanced
303 pancreatic cancer-induced portal biliary disease [30].

304 **The complications of stent placement in bile duct neoplasms and pancreatic neoplasms**

305 As for pancreatic neoplasms, preoperative biliary drainage (PBD) promotes complications
306 compared with surgery without PBD. The result could be associated with the plastic stents
307 utilized. However, metal stents might decrease the PBD-associated complications [31]. It has
308 been confirmed that biliary stents could remarkably increase liver volume in both hilar and
309 distal bile duct neoplasms [32]. Endoscopic retrograde biliary drainage of metal bile duct stents
310 are widely used for biliary obstruction. The application of bile duct stents has also led to an
311 increasing number of complications. The main complications of pancreatic stents include
312 migration, stent occlusion, and pancreatic ductal changes [33].

313 **Postoperative complications after stent placement such as pancreaticoduodenectomy**

314 Pancreatic fistula is a leading complication following pancreaticoduodenectomy. Pessaux P
315 et al. have reported that external pancreatic duct stent reduces pancreatic fistula rate following
316 pancreaticoduodenectomy [34]. Obstructive jaundice is one of the known risk factors for
317 treatment failure following hepatectomy for patients with hilar cholangiocarcinoma. In palliative
318 care, self-expanding metal stents have a rapid reduction in bile duct pressure and reduce

319 complication rates, while providing patients with adequate and rapid biliary drainage [35].

320 **Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy**

321 It is necessary to prevent pancreatic fistula after pancreaticoduodenectomy in stent
322 placement. The incidence of pancreatic fistula in patients undergoing pancreaticoduodenectomy
323 is as high as 56% and is considered to be a main factor on morbidity and mortality in patients
324 following pancreaticoduodenectomy [36, 37]. And external duct stents placement could reduce
325 the occurrence for clinically relevant postoperative pancreatic fistula [38].

326 **Prophylactic pancreatic duct stent can reduce the incidence of post-ERCP pancreatitis 327 (PEP) and complications such as pancreatitis associated with stent implantation**

328 Endoscopic retrograde ERCP was first introduced in 1968. As a diagnostic tool, it was used
329 to assess the disorders of pancreas [39]. As a most common complication of ERCP, the incidence
330 of PEP is still as high as 15% in high-risk cases [40]. And a small number of patients could
331 develop severe pancreatitis. Pancreatitis is a common and serious complication for endoscopic
332 retrograde ERCP. Prevention of pancreatitis after ERCP remains the focus of clinical and
333 research. Relevant strategies could decrease the occurrence of post-ERCP pancreatitis including
334 patient selection, risk stratification, surgical techniques, pancreatic stenting, and drug
335 prophylaxis. Placement of the pancreatic stent is a relatively new and increasingly popular
336 method of reducing the risk of pancreatitis after ERCP [41]. Prophylactic pancreatic stent
337 placement decreases the incidence of pancreatitis after ERCP in high risk patients and reduces
338 the severity of this condition [42]. In summary, placement for pancreatic duct stent decreases the
339 incidence of pancreatitis [43].

340 **Pancreatic duct changes in patients with chronic pancreatitis**

341 It is essential to prevent pancreatic duct changes such as pancreatic leakage or
342 pancreatic duct patency after pancreaticoduodenectomy. In duct-to-mucosa
343 anastomosis, placement of the stent could be an effective mean of dilating the pancreatic duct
344 [44]. Pancreatic stent is used to improve painful, obstructive chronic pancreatitis [45].

345 **Stent placement in endoscopic pancreatic pseudocyst drainage**

346 Pancreatic pseudocyst is one of the common local complications of acute and chronic
347 pancreatitis. And endoscopic pancreatic pseudocyst drainage has been widely applied in the
348 treatment of pancreatic pseudocysts [46]. Endoscopic drainage has the advantages of small
349 invasiveness, short recovery time, low cost and low complication rate [47], like interventional
350 endoscopic ultrasonography has been increasingly used to manage pseudocyst formation [48]. As
351 an example, Varadarajulu S et al. have found that, compared with surgical bladder anastomosis,
352 patients with endoscopy pancreatic pseudocyst drainage experience rarely recurrence of
353 pseudocyst during follow-up [49].

354 **Conclusion:**

355 We analyzed the literature on pancreatic stents based on bibliometric analysis. Finally, 83
356 high-frequent MeSH terms and 8 topics were found. And we found how to reduce the incidence
357 of postoperative complications and improve the prognosis of patients with pancreatic diseases by
358 stent implantation is still the focus of future research. This conclusion could provide potential

359 and invaluable insight for researchers in the further research.

360 **Abbreviations:**

361 MeSH: Medical Subject Headings; BICOMB: Bibliographic Item Co-Occurrence Matrix
362 Builder; PMIDs: PubMed Unique Identifiers; PBD: preoperative biliary drainage; ERCP:
363 cholangiopancreatography.

364 **Acknowledgments:** Not applicable.

365 **References:**

- 366 [1] Briggs CD, Irving GR, Cresswell A, Peck R, Lee F, Peterson M, Cameron IC. Percutaneous
367 transhepatic insertion of self-expanding short metal stents for biliary obstruction before resection
368 of pancreatic or duodenal malignancy proves to be safe and effective. *Surg Endosc.* 2010,
369 24(3):567-71.
- 370 [2] Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, Li HL, Wang WH, Li YL, Ni CF, Shi HB,
371 Xiao EH, Lv WF, Sun JH, Xu K, Han GH, Du LA, Ren WX, Li MQ, Mao AW, Xiang H, Zhang
372 KX, Min J, Zhu GY, Su C, Chen L, Teng GJ. Irradiation stents vs. conventional metal stents for
373 unresectable malignant biliary obstruction: A multicenter trial. *J Hepatol.* 2018, 68(5):970-977.
- 374 [3] Baron TH. Best endoscopic stents for the biliary tree and pancreas. *Curr Opin Gastroenterol.*
375 2014, 30(5):453-6.
- 376 [4] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics,
377 2012. *CA Cancer J Clin.* 2015, 65(2):87-108.
- 378 [5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin.* 2018, 68(1):7-30.
- 379 [6] Haapamäki C, Kylänpää L, Udd M, Lindström O, Grönroos J, Saarela A, Mustonen H,
380 Halttunen J. Randomized multicenter study of multiple plastic stents vs. covered self-expandable
381 metallic stent in the treatment of biliary stricture in chronic pancreatitis. *Endoscopy.* 2015,
382 47(7):605-10.
- 383 [7] Su H, Lee P. Mapping knowledge structure by keyword co-occurrence: a first look at journal
384 papers in *Technology Foresight*. *Scientometrics* 2010, 85(1):65-79.
- 385 [8] Thompson DF, Walker CK. A descriptive and historical review of bibliometrics with
386 applications to medical sciences. *Pharmacotherapy.* 2015, 35(6):551-9.
- 387 [9] Yao Q, Chen K, Yao L, Lyu PH, Yang TA, Luo F, Chen SQ, He LY, Liu ZY. Scientometric
388 trends and knowledge maps of global health systems research. *Health Res Policy Syst.* 2014,
389 12:26.
- 390 [10] Hong Y, Yao Q, Yang Y, Feng JJ, Wu SD, Ji WX, Yao L, Liu ZY. Knowledge structure
391 and theme trends analysis on general practitioner research: a cword perspective. *BMC Fam*
392 *Pract.* 2016, 17:10.
- 393 [11] Zhang Z, Murtagh F, Van Poucke S, Lin S, Lan P. Hierarchical cluster analysis in clinical
394 research with heterogeneous study population: Highlighting its visualization with R. *Ann Transl*
395 *Med.* 2017, 5(4): 75.
- 396 [12] Cheng Y, Church GM. Bicustering of expression data. Eighth International Conference on

- 397 Intelligent Systems for Molecular Biology AAAI Press. 2000, 8: 93–103.
- 398 [13] Hartigan JA. Direct clustering of a data matrix. *Publications of the American Statistical*
399 *Association*. 1978, 67(337): 123–29.
- 400 [14] Le NQK, Huynh TT, Yapp EKY, Yeh HY. Identification of clathrin proteins by
401 incorporating hyperparameter optimization in deep learning and PSSM profiles. *Computer*
402 *Methods and Programs in Biomedicine*. 2019, 177: 81-88.
- 403 [15] Le NQ. iN6-methylat (5-step): identifying DNA N6-methyladenine sites in rice genome
404 using continuous bag of nucleobases via Chou's 5-step rule. *Molecular Genetics and Genomics*.
405 2019.
- 406 [16] Doms A, Schroeder M. GoPubMed: exploring PubMed with the Gene Ontology. *Nucleic*
407 *Acids Res*. 2005, 33:W783-6.
- 408 [17] Mandrekar JN. Measures of interrater agreement. *J Thorac Oncol*. 2011, 6(1):6-7.
- 409 [18] T. Dehdarirad, A. Villarroya, M. Barrios. Research trends in gender differences in higher
410 education and science: a co-word analysis, *Scientometrics*. 2014, 101: 273-290.
- 411 [19] J. Hu, Y. Zhang. Research patterns and trends of Recommendation System in China using
412 co-word analysis. *Information Processing & Management*. 2015, 51: 329-33.
- 413 [20] Cui Lei, Liu Wei, Yan Lei, Zhang Han, Hou Yuefang, Huang Yingna, Zhang Hao.
414 Development of a text mining system based on the co-occurrence of bibliographic items in
415 literature. *New Technology of Library and Information Service*. 2008, (8):70-75.
- 416 [21] Le NQ, Ou YY. Prediction of FAD binding sites in electron transport proteins according to
417 efficient radial basis function networks and significant amino acid pairs. *BMC Bioinformatics*.
418 2016, 17:298.
- 419 [22] Le NQ, Ho QT, Ou YY. Using two-dimensional convolutional neural networks for
420 identifying GTP binding sites in Rab proteins. *J Bioinform Comput Biol*. 2019, 17(1):1950005.
- 421 [23] Karypis Lab. Webcite gCLUTO-Graphical Clustering Toolkit. 2014.
- 422 [24] Li F, Li M, Guan P, Ma S, Cui L. Mapping publication trends and identifying hot spots of
423 research on Internet health information seeking behavior: a quantitative and co-word biclustering
424 analysis. *J Med Internet Res*. 2015, 17(3):e81.
- 425 [25] Callon M, Courtial J P, Laville F. Co-word analysis as a tool for describing the network of
426 interactions between basic and technology research: the case of polymer chemistry.
427 *Scientometrics*. 1991, 22(1): 155-205.
- 428 [26] Indolfi L, Ligorio M2 Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs
429 BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A
430 tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
431 *Biomaterials*. 2016, 93:71-82.
- 432 [27] Shi B, Wei W, Qin X, Zhao F, Duan Y, Sun W, Li D, Cao Y. Mapping theme trends and
433 knowledge structure on adipose-derived stem cells: a bibliometric analysis from 2003 to 2017.
434 *Regen Med*. 2019, 14(1):33-48.
- 435 [28] Aadam AA, Evans DB, Khan A, Oh Y, Dua K. Efficacy and safety of self-expandable metal
436 stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer:
437 a prospective study. *Gastrointest Endosc*. 2012, 76(1):67-75.

- 438 [29] van der Horst A, Lens E, Wognum S, de Jong R, van Hooft JE, van Tienhoven G, Bel A.
439 Limited role for biliary stent as surrogate fiducial marker in pancreatic cancer: stent and
440 intratumoral fiducials compared. *Int J Radiat Oncol Biol Phys*. 2014, 89(3):641-8.
- 441 [30] Kim SY, Cho JH, Kim EJ, Choi SJ, Kim YS. Successful hemostasis using a covered self-
442 expandable metallic stent for spurting hemobilia in patients with advanced pancreatic cancer-
443 induced portal biliopathy. *Gastrointest Endosc*. 2016, 84(5):858-860.
- 444 [31] Tol JA, van Hooft JE, Timmer R, Kubben FJ, van der Harst E, de Hingh IH, Vleggaar FP,
445 Molenaar IQ, Keulemans YC, Boerma D, Bruno MJ, Schoon EJ, van der Gaag NA, Besselink
446 MG, Fockens P, van Gulik TM, Rauws EA, Busch OR, Gouma DJ. Metal or plastic stents for
447 preoperative biliary drainage in resectable pancreatic cancer. *Gut*. 2016, 65(12):1981-1987.
- 448 [32] Lee CH, Kim SH, Kim IH, Kim SW, Lee ST, Kim DG, Yang JD, Yu HC, Cho BH, Lee SO.
449 Endoscopic stenting in bile duct cancer increases liver volume. *Gastrointest Endosc*. 2014,
450 80(3):447-55.
- 451 [33] ASGE Technology Assessment Committee, Pfau PR, Pleskow DK, Banerjee S, Barth BA,
452 Bhat YM, Desilets DJ, Gottlieb KT, Maple JT, Siddiqui UD, Tokar JL, Wang A, Song LM,
453 Rodriguez SA. Pancreatic and biliary stents. *Gastrointest Endosc*. 2013, 77(3):319-27.
- 454 [34] Pessaux P, Sauvanet A, Mariette C, Paye F, Muscari F, Cunha AS, Sastre B, Arnaud JP;
455 Fédération de Recherche en Chirurgie (French). External pancreatic duct stent decreases
456 pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial.
457 *Ann Surg*. 2011, 253(5):879-85.
- 458 [35] Grünhagen DJ, Dunne DF, Sturgess RP, Stern N, Hood S, Fenwick SW, Poston GJ, Malik
459 HZ. Metal stents: a bridge to surgery in hilar cholangiocarcinoma. *HPB (Oxford)*. 2013,
460 15(5):372-8.
- 461 [36] Dong Z, Xu J, Wang Z, Petrov MS. Stents for the prevention of pancreatic fistula following
462 pancreaticoduodenectomy. *Cochrane Database Syst Rev*. 2016, (5):CD008914.
- 463 [37] Brown EG, Yang A, Canter RJ, Bold RJ. Outcomes of pancreaticoduodenectomy: where
464 should we focus our efforts on improving outcomes? *JAMA Surgery* 2014, 147 (7):694–9.
- 465 [38] Motoi F, Egawa S, Rikiyama T, Katayose Y, Unno M. Randomized clinical trial of external
466 stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after
467 pancreaticojejunostomy. *Br J Surg*. 2012, 99(4):524-31.
- 468 [39] Riff BP, Chandrasekhara V. The Role of Endoscopic Retrograde Cholangiopancreatography
469 in Management of Pancreatic Diseases. *Gastroenterol Clin North Am*. 2016, 45(1):45-65.
- 470 [40] Elmunzer BJ. Reducing the risk of post-endoscopic retrograde cholangiopancreatography
471 pancreatitis. *Dig Endosc*. 2017, 29(7):749-757.
- 472 [41] Shi QQ, Ning XY, Zhan LL, Tang GD, Lv XP. Placement of prophylactic pancreatic stents
473 to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk
474 patients: a meta-analysis. *World J Gastroenterol*. 2014, 20(22):7040-8.
- 475 [42] Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde
476 cholangiopancreatography pancreatitis. *Clin Gastroenterol Hepatol*. 2007, 5(11):1354-65.
- 477 [43] Sofuni A, Maguchi H, Mukai T, Kawakami H, Irisawa A, Kubota K, Okaniwa S, Kikuyama
478 M, Kutsumi H, Hanada K, Ueki T, Itoi T. Endoscopic pancreatic duct stents reduce the incidence

- 479 of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. *Clin*
480 *Gastroenterol Hepatol.* 2011, 9(10):851-8.
- 481 [44] Téllez-Aviña FI, Casasola-Sánchez LE, Ramírez-Luna MÁ, Saúl Á, Murcio-Pérez E, Chan
482 C, Uscanga L, Duarte-Medrano G, Valdovinos-Andraca F. Permanent Indwelling Transmural
483 Stents for Endoscopic Treatment of Patients With Disconnected Pancreatic Duct Syndrome:
484 Long-term Results. *J Clin Gastroenterol.* 201, 52(1):85-90.
- 485 [45] Samuelson A, Zeligman B, Russ P, Austin GL, Yen R, Shah RJ. Pancreatic Duct Changes in
486 Patients with Chronic Pancreatitis Treated With Polyethylene and Sof-Flex Material Stents: A
487 Blinded Comparison. *Pancreas.* 2016, 45(2):281-5.
- 488 [46] Madder RD, Khan M, Husaini M, Chi M, Dionne S, VanOosterhout S, Borgman A, Collins
489 JS, Jacoby M. Combined Near-Infrared Spectroscopy and Intravascular Ultrasound Imaging of
490 Pre-Existing Coronary Artery Stents: Can Near-Infrared Spectroscopy Reliably Detect
491 Neoatherosclerosis? *Circ Cardiovasc Imaging.* 2016, 9(1): e003576.
- 492 [47] Shah RJ, Shah JN, Waxman I, Kowalski TE, Sanchez-Yague A, Nieto J, Brauer BC,
493 Gaidhane M, Kahaleh M. Safety and efficacy of endoscopic ultrasound-guided drainage of
494 pancreatic fluid collections with lumen-apposing covered self-expanding metal stents. *Clin*
495 *Gastroenterol Hepatol.* 2015, 13(4):747-52.
- 496 [48] Vilmann AS, Menachery J, Tang SJ, Srinivasan I, Vilmann P. Endosonography guided
497 management of pancreatic fluid collections. *World J Gastroenterology.* 2015, 21(41):11842-53.
- 498 [49] Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM. Equal efficacy
499 of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized
500 trial. *Gastroenterology.* 2013, 145(3):583-90.

501 **Figure legends:**

- 502 Figure 1. The information of literature on the application of stents in pancreatic diseases. A. The
503 growth of literature publications about the application of stents in pancreatic diseases from 1977
504 to 2018; B. Geographic distribution of research outputs on the application of stents in pancreatic
505 diseases; C. Annual distribution of MeSH terms about the application of stents in pancreatic
506 diseases.
- 507 Figure 2. A mountain visualization biclustering of 83 high-frequent major MeSH terms and
508 papers on the application of stents in pancreatic diseases.
- 509 Figure 3. A visualized matrix biclustering of highly frequent major MeSH terms and PubMed
510 Unique Identifiers (PMIDs) of articles on the application of stents in pancreatic diseases.
- 511 Figure 4. Strategic diagram for the application of stents in pancreatic diseases. (A) The meaning
512 of strategic diagram. (B) The strategic diagram of the 8 clusters for the application of stents in
513 pancreatic diseases.
- 514 Figure 5. Social network analysis. A. The top 29 author relationship network. The size and
515 location of nodes represent the centrality of an author in the social network. B. The network of
516 high-frequent major MeSH terms. Nodes suggest high-frequent major MeSH terms. The size and
517 location of nodes represent the centrality of a MeSH term in the network structure map. Links
518 stand for the connection between MeSH terms, and the number or thickness of the lines stands

519 for the co-occurrence frequency of high-frequent major MeSH terms.
520 Table 1. The 29 top authors from the listed publications on the application of stents in pancreatic
521 diseases (PubMed sourced until May 2018).
522 Table 2. Most active journals on the topic of the application of stents in pancreatic diseases
523 (PubMed sourced until May 2018).
524 Table 3. 83 high-frequent major MeSH terms from the listed publications on the application of
525 stents in pancreatic diseases.
526 Table 4. The centrality and density of the 8 clusters about the application of stents in pancreatic
527 diseases.
528 Table 5. The cluster analysis of 8 clusters the application of stents in pancreatic diseases.

Figure 1

The information of literature on the application of stents in pancreatic diseases.

A. The growth of literature publications about the application of stents in pancreatic diseases from 1977 to 2018; B. Geographic distribution of research outputs on the application of stents in pancreatic diseases; C. Annual distribution of MeSH terms about the application of stents in pancreatic diseases.





Figure 2

A mountain visualization biclustering of 83 high-frequent major MeSH terms and papers on the application of stents in pancreatic diseases.



Cluster	MeSH Terms	
0	Pancreatic Neoplasms / pathology	
	Pancreatic Neoplasms / therapy	
	Pancreatic Neoplasms / diagnosis	
	Cholestasis, Extrahepatic / etiology	
	Radiography	
	Pancreatic Neoplasms / diagnostic imaging	
	Diagnosis, Differential	
1	Cholestasis, Extrahepatic / therapy	
	Pancreatic Neoplasms / complications	
	Stents / adverse effects	
	Cholestasis / etiology	
	Palliative Care	
	Cholestasis / therapy	
	Cholestasis / surgery	
	Metals	
	Prosthesis Design	
	Equipment Design	
	Palliative Care / methods	
Bile Duct Neoplasms / complications		
2	Pancreatic Neoplasms / surgery	
	Jaundice, Obstructive / etiology	
	Survival Rate	
	Pancreaticoduodenectomy	
	Pancreatic Neoplasms / mortality	
	Postoperative Complications	
	Prognosis	
	Ampulla of Vater / surgery	
	Ampulla of Vater	
	Jaundice, Obstructive / surgery	
	Common Bile Duct Neoplasms / surgery	
Adenocarcinoma / surgery		
3	Stents	
	Treatment Outcome	
	Retrospective Studies	
	Follow-Up Studies	
	Tomography, X-Ray Computed	
	Prospective Studies	
	Time Factors	
	Drainage	
	Pancreas / surgery	
	Pancreatic Diseases / surgery	
	Pancreatic Fistula / etiology	
Pancreaticoduodenectomy / adverse effects		
Postoperative Complications / etiology		
Postoperative Complications / epidemiology		
4	Pancreatitis / etiology	
	Cholangiopancreatography, Endoscopic Retrograde / adverse effects	
	Cholangiopancreatography, Endoscopic Retrograde / methods	
	Risk Factors	
	Pancreatic Ducts	
	Pancreatitis / prevention & control	
	Cholangiopancreatography, Endoscopic Retrograde / instrumentation	
	Sphincterotomy, Endoscopic / methods	
	Risk Assessment	
	Cholangiopancreatography, Endoscopic Retrograde	
	5	Chronic Disease
Sphincterotomy, Endoscopic		
Recurrence		
Pancreatitis / complications		
Pancreatitis / surgery		
Acute Disease		
Pancreatitis / therapy		
Endoscopy		
Pancreatitis / diagnosis		
Pancreatic Ducts / surgery		
6		Endoscopy, Digestive System
	Pancreatic Ducts / pathology	
	Pancreatic Ducts / diagnostic imaging	
	Constriction, Pathologic / therapy	
	Constriction, Pathologic / etiology	
	Pancreatic Diseases / therapy	
	Constriction, Pathologic	
	Constriction, Pathologic / surgery	
	Pancreatitis, Chronic / complications	
	7	Drainage / methods
		Endosonography
Drainage / instrumentation		
Pancreatic Pseudocyst / surgery		
Endoscopy, Digestive System / methods		
Endosonography / methods		
Pancreatic Pseudocyst / diagnostic imaging		
Ultrasonography, Interventional		
Pancreatic Pseudocyst / therapy		

Figure 3

A visualized matrix biclustering of highly frequent major MeSH terms and PubMed Unique Identifiers (PMIDs) of articles on the application of stents in pancreatic diseases.




Figure 4

Strategic diagram for the application of stents in pancreatic diseases.

(A) The meaning of strategic diagram. (B) The strategic diagram of the 8 clusters for the application of stents in pancreatic diseases.




Figure 5

Social network analysis.

A. The top 29 author relationship network. The size and location of nodes represent the centrality of an author in the social network. B. The network of high-frequent major MeSH terms. Nodes suggest high-frequent major MeSH terms. The size and location of nodes represent the centrality of a MeSH term in the network structure map. Links stand for the connection between MeSH terms, and the number or thickness of the lines stands for the co-occurrence frequency of high-frequent major MeSH terms.




Table 1 (on next page)

The 29 top authors from the listed publications on the application of stents in pancreatic diseases (PubMed sourced until May 2018).

1 Table 1. The 29 top authors from the listed publications on the application of stents in pancreatic
 2 diseases (PubMed sourced until May 2018)

No.	Author	Frequency	Percentage, % ^a	Cumulative percentage, %
1	Baron TH	84	2.0468	2.0468
2	Kahaleh M	81	1.9737	4.0205
3	Isayama H	65	1.5838	5.6043
4	Itoi T	58	1.4133	7.0175
5	Nakai Y	50	1.2183	8.2359
6	Varadarajulu S	49	1.194	9.4298
7	Sherman S	46	1.1209	10.5507
8	Lehman GA	41	0.999	11.5497
9	Costamagna G	39	0.9503	12.5
10	Tada M	39	0.9503	13.4503
11	Bhasin DK	38	0.9259	14.3762
12	Koike K	37	0.9016	15.2778
13	Rana SS	37	0.9016	16.1793
14	Devière J	36	0.8772	17.0565
15	Freeman ML	36	0.8772	17.9337
16	Kogure H	36	0.8772	18.8109
17	Kozarek RA	35	0.8528	19.6637
18	Hirano K	32	0.7797	20.4435
19	Ito K	31	0.7554	21.1988
20	Wilcox CM	31	0.7554	21.9542
21	Sasahira N	31	0.7554	22.7096
22	Sasaki T	30	0.731	23.4405
23	Huibregtse K	27	0.6579	24.0984
24	Kim MH	27	0.6579	24.7563
25	Yamamoto N	27	0.6579	25.4142
26	Khashab MA	26	0.6335	26.0478
27	Lee JH	26	0.6335	26.6813
28	Gupta R	26	0.6335	27.3148
29	Adler DG	26	0.6335	27.9483
	Total	1147		

3 ^aProportion of the frequency among 1147 times' appearance.

Table 2 (on next page)

Most active journals on the topic of the application of stents in pancreatic diseases (PubMed sourced until May 2018).

1 Table 2. Most active journals on the topic of the application of stents in pancreatic diseases
 2 (PubMed sourced until May 2018)

No.	Top journals	Publications n (%)
1	Gastrointestinal endoscopy	517(12.55)
2	Endoscopy	339(8.23)
3	World journal of gastroenterology	107(2.60)
4	Surgical endoscopy	101(2.45)
5	Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society	87(2.11)
6	The American journal of gastroenterology	76(1.85)
7	Hepato-gastroenterology	76(1.85)
8	Cardiovascular and interventional radiology	61(1.48)
9	Gastrointestinal endoscopy clinics of North America	61(1.48)
10	Digestive diseases and sciences	59(1.43)
11	JOP : Journal of the pancreas	51(1.24)
12	Journal of gastroenterology and hepatology	51(1.24)
13	Journal of vascular and interventional radiology : JVIR	48(1.17)
14	Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract	45(1.09)
15	Journal of clinical gastroenterology	45(1.09)
16	Pancreas	44(1.07)
17	Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.]	40(0.97)
18	World journal of gastrointestinal endoscopy	35(0.85)
19	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association	33(0.80)
20	Gut	33(0.80)
21	Endoscopic ultrasound	32(0.78)
22	HPB : the official journal of the International Hepato Pancreato Biliary Association	30(0.73)
23	Gan to kagaku ryoho. Cancer & chemotherapy	29(0.70)
24	Journal of hepato-biliary-pancreatic sciences	29(0.70)
25	Annals of surgery	27(0.66)
	Total	2056(49.92)

3

Table 3(on next page)

83 high-frequent major MeSH terms from the listed publications on the application of stents in pancreatic diseases.

1 Table 3. 83 High-frequent major MeSH terms from the listed publications on the application of
 2 stents in pancreatic diseases

No.	Major MeSH ^a terms/ MeSH subheadings	Frequency, n	Percentage, % ^b	Cumulative percentage, %
1	Stents	2238	3.8488	13.9489
2	Treatment Outcome	1038	1.7851	27.731
3	Retrospective Studies	758	1.3036	30.3725
4	Cholangiopancreatography, Endoscopic Retrograde	677	1.1643	31.5368
5	Pancreatic Neoplasms / complications	544	0.9355	32.4723
6	Follow-Up Studies	472	0.8117	33.284
7	Drainage / methods	452	0.7773	34.0614
8	Pancreatic Neoplasms / surgery	449	0.7722	34.8335
9	Stents / adverse effects	401	0.6896	35.5231
10	Cholestasis / etiology	379	0.6518	36.1749
11	Tomography, X-Ray Computed	371	0.638	36.813
12	Pancreatitis / etiology	338	0.5813	37.3942
13	Cholangiopancreatography, Endoscopic Retrograde / adverse effects	335	0.5761	37.9704
14	Cholangiopancreatography, Endoscopic Retrograde / methods	314	0.54	38.5104
15	Prospective Studies	297	0.5108	39.0211
16	Pancreatic Ducts / surgery	295	0.5073	39.5284
17	Time Factors	289	0.497	40.0255
18	Drainage	281	0.4832	40.5087
19	Palliative Care	270	0.4643	40.973
20	Endosonography	254	0.4368	41.4099
21	Cholestasis / therapy	250	0.4299	42.2766
22	Risk Factors	244	0.4196	42.6962
23	Pancreatic Neoplasms / pathology	238	0.4093	43.1055
24	Cholestasis / surgery	226	0.3887	43.4942
25	Chronic Disease	198	0.3405	43.8347
26	Drainage / instrumentation	195	0.3354	44.17
27	Metals	185	0.3182	44.4882
28	Pancreatic Ducts	184	0.3164	44.8046
29	Sphincterotomy, Endoscopic	182	0.313	45.1176
30	Pancreatic Pseudocyst / surgery	182	0.313	45.4306
31	Recurrence	179	0.3078	45.7385
32	Pancreatitis / complications	177	0.3044	46.0429
33	Pancreatitis / surgery	176	0.3027	46.3455
34	Pancreatic Neoplasms / therapy	169	0.2906	46.6362
35	Jaundice, Obstructive / etiology	164	0.282	46.9182

36	Prosthesis Design	164	0.282	47.2002
37	Pancreatitis / prevention & control	164	0.282	47.4823
38	Acute Disease	163	0.2803	47.7626
39	Equipment Design	162	0.2786	48.0412
40	Palliative Care / methods	158	0.2717	48.3129
41	Bile Duct Neoplasms / complications	157	0.27	48.5829
42	Pancreatitis / therapy	151	0.2597	49.1057
43	Endoscopy, Digestive System	150	0.258	49.3637
44	Endoscopy, Digestive System / methods	146	0.2511	49.6148
45	Survival Rate	144	0.2476	49.8624
46	Pancreas / surgery	143	0.2459	50.1083
47	Pancreatic Diseases / surgery	132	0.227	50.5692
48	Cholangiopancreatography, Endoscopic Retrograde / instrumentation	131	0.2253	50.7945
49	Pancreaticoduodenectomy	130	0.2236	51.0181
50	Pancreatic Neoplasms / mortality	128	0.2201	51.2382
51	Pancreatic Fistula / etiology	127	0.2184	51.4566
52	Postoperative Complications	127	0.2184	51.675
53	Endosonography / methods	125	0.215	51.89
54	Prognosis	125	0.215	52.105
55	Pancreatic Ducts / pathology	122	0.2098	52.3148
56	Pancreatic Neoplasms / diagnosis	121	0.2081	52.5229
57	Endoscopy	119	0.2047	52.7275
58	Cholestasis, Extrahepatic / etiology	117	0.2012	52.9287
59	Pancreatic Ducts / diagnostic imaging	116	0.1995	53.1282
60	Pancreaticoduodenectomy / adverse effects	115	0.1978	53.326
61	Sphincterotomy, Endoscopic / methods	114	0.1961	53.522
62	Constriction, Pathologic / therapy	114	0.1961	53.7181
63	Pancreatic Pseudocyst / diagnostic imaging	113	0.1943	53.9124
64	Constriction, Pathologic / etiology	113	0.1943	54.1068
65	Risk Assessment	113	0.1943	54.3011
66	Ultrasonography, Interventional	112	0.1926	54.4937
67	Postoperative Complications / etiology	112	0.1926	54.6863
68	Pancreatic Diseases / therapy	112	0.1926	54.8789
69	Radiography	110	0.1892	55.0681
70	Pancreatic Pseudocyst / therapy	110	0.1892	55.2573
71	Ampulla of Vater / surgery	110	0.1892	55.4464
72	Pancreatic Neoplasms / diagnostic imaging	109	0.1875	55.6339
73	Ampulla of Vater	109	0.1875	55.8214
74	Jaundice, Obstructive / surgery	108	0.1857	56.0071
75	Common Bile Duct Neoplasms / surgery	107	0.184	56.1911

76	Adenocarcinoma / surgery	106	0.1823	56.3734
77	Pancreatitis / diagnosis	101	0.1737	56.5471
78	Constriction, Pathologic	101	0.1737	56.7208
79	Diagnosis, Differential	97	0.1668	56.8876
80	Postoperative Complications / epidemiology	95	0.1634	57.051
81	Constriction, Pathologic / surgery	94	0.1617	57.2126
82	Cholestasis, Extrahepatic / therapy	92	0.1582	57.3708
83	Pancreatitis, Chronic / complications	92	0.1582	57.5291

3 ^a MeSH: Medical Subject Headings

4 ^b Proportion of the frequency among 19282 times' appearance.

Table 4(on next page)

The centrality and density of the 8 clusters about the application of stents in pancreatic diseases.

1 Table 4. The centrality and density of the 8 clusters

cluster	Intra-class link		Intra-class	
	averages	centrality-X	link averages	density-Y
0	8.446666667	-4.62712	33.16071429	-22.7996
1	15.29292929	2.219142	75.47272727	19.51241
2	9.875586854	-3.1982	31.62878788	-24.3315
3	24.98033126	11.90654	98.67032967	42.71001
4	12.63963964	-0.43415	68.26388889	12.30357
5	13.39589041	0.322103	55.3	-0.66032
6	8.673972603	-4.39982	27.58888889	-28.3714
7	11.28528529	-1.7885	57.59722222	1.636902
total	13.07378775		55.96031989	

2

Table 5 (on next page)

The cluster analysis of 8 clusters the application of stents in pancreatic diseases.

1 Table 5. The cluster analysis of 8 clusters

Cluster	Number of MeSH terms ^a	Cluster analysis
0	23,34,56,58,69,72,79,82	Stents placement in pancreatic neoplasms
1	5,9,10,19,21,24,27,36,39,40,41	The complications of stents placement in bile duct neoplasms and pancreatic neoplasms
2	8,35,45,49,50,52,54,71,73,74,75,76	postoperative complications after stent placement such as pancreaticoduodenectomy
3	1,2,3,6,11,15,17,18,46,47,51,60,67,80	Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy
4	12,13,14,22,28,37,48,61,65	Prophylactic pancreatic duct stent can reduce the incidence of post-ERCP pancreatitis (PEP)
5	4,25,29,31,32,33,38,42,57,77	The diagnosis, surgery and therapy of pancreatitis
6	16,43,55,59,62,64,68,78,81,83	Pancreatic ducts changes in patients with chronic pancreatitis
7	7,21,26,30,44,53,63,66,70	Stent placement in endoscopic pancreatic pseudocyst drainage

2 a represents the serial number of high-frequency MeSH terms.